戻る
Rafael Holdings Inc (RFL)価格
RFL 株価推移チャート
RFL 収入
Rafael Holdings Inc
$1.2
0%
$0
終値： Feb 11, 16:00:00 GMT-5
$1.22
2.34%
$0.02
プレマーケット： Feb 12, 08:22:04 GMT-5
最新の利益結果: Q1 '25
報告済み: 2024-12-11
歴史的収益
四半期
年次
EPS
収入
Earnings FAQ
RFLの最近の1株当たり利益（EPS）は予想と比較してどうでしたか？
Rafael Holdings Inc RFLの前四半期の収益はどうでしたか？
Rafael Holdings Incの収益見積もりはいくらですか？
Rafael Holdings Incの収益品質スコアはどれくらいですか？
Rafael Holdings Incはいつ収益を報告しますか？
Rafael Holdings Incの予想収益はいくらですか？
Rafael Holdings Incは収益予想を上回りましたか？
主要データ
前終値
$1.2
始値
$1.2
当日レンジ
$1.2 - $1.23
52週レンジ
$1.12 - $3.19
取引高
33.1K
平均取引高
126.4K
1株当たり利益(TTM)
-0.85
配当利回り
--
時価総額
$63.5M
RFLとは何ですか？
Rafael Holdings, Inc. owns an interest in clinical and early-stage pharmaceutical companies. The company is headquartered in Newark, New Jersey and currently employs 21 full-time employees. The company went IPO on 2018-03-12. The firm's segments include Healthcare, Infusion Technology and Real Estate. The Company’s lead candidate is Trappsol Cyclo, which is being evaluated in clinical trials for the potential treatment of Niemann-Pick Disease Type C1 (NPC1), a rare, fatal and progressive genetic disorder. The Healthcare segment comprises equity interests in LipoMedix Pharmaceuticals Ltd., Barer Institute Inc., Cornerstone Pharmaceuticals, Inc., Cyclo, and Rafael Medical Devices, LLC. The Real Estate segment consists of the Company’s real estate holdings, which comprise a portion of one commercial building in Israel. The Infusion Technology segment comprises equity interests in Day Three Labs, Inc. LipoMedix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company.